Literature DB >> 19520906

Impact of the lung allocation score on lung transplantation for pulmonary arterial hypertension.

Hubert Chen1, Stephen C Shiboski, Jeffrey A Golden, Michael K Gould, Steven R Hays, Charles W Hoopes, Teresa De Marco.   

Abstract

RATIONALE: In 2005, lung allocation for transplantation in the United States changed from a system based on waiting time to a system based on the Lung Allocation Score (LAS).
OBJECTIVES: To study the effect of the LAS on lung transplantation for idiopathic pulmonary arterial hypertension (IPAH) compared with other major diagnoses.
METHODS: We studied 7,952 adults listed for lung transplantation between 2002 and 2008. Analyses were restricted to patients with IPAH, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). Transplantation, waiting list mortality, and post-transplant mortality were compared between diagnoses for patients listed before and after implementation of the LAS.
MEASUREMENTS AND MAIN RESULTS: The likelihood of transplantation from the waiting list increased for all diagnoses after implementation of the LAS. Waiting list mortality decreased for every diagnosis, except for IPAH, which remained unchanged. Implementation of the LAS was not associated with changes in post-transplant mortality for any diagnosis. Under the LAS system, patients with IPAH were less likely to be transplanted than patients with IPF (hazard ratio [HR], 0.53; P < 0.001) or CF (HR, 0.49; P < 0.001) and at greater risk of death on the waiting list than patients with COPD (HR, 3.09; P < 0.001) or CF (HR, 1.83; P = 0.025) after adjustment for demographics and transplant type. Post-transplant mortality for IPAH was not statistically different from that of other diagnoses.
CONCLUSIONS: Implementation of the LAS has improved the likelihood of lung transplantation for listed patients with IPAH, but mortality on the waiting list remains high compared with other major diagnoses.

Entities:  

Mesh:

Year:  2009        PMID: 19520906      PMCID: PMC2742763          DOI: 10.1164/rccm.200810-1603OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  16 in total

Review 1.  Multi-state models for event history analysis.

Authors:  Per Kragh Andersen; Niels Keiding
Journal:  Stat Methods Med Res       Date:  2002-04       Impact factor: 3.021

2.  Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.

Authors:  Lewis J Rubin
Journal:  Chest       Date:  2004-07       Impact factor: 9.410

3.  Thoracic organ transplantation in the United States, 1994-2003.

Authors:  Mark L Barr; Robert C Bourge; Jonathan B Orens; Kenneth R McCurry; W Steves Ring; Tempie E Hulbert-Shearon; Robert M Merion
Journal:  Am J Transplant       Date:  2005-04       Impact factor: 8.086

4.  Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension.

Authors:  N Nagaya; T Nishikimi; M Uematsu; T Satoh; S Kyotani; F Sakamaki; M Kakishita; K Fukushima; Y Okano; N Nakanishi; K Miyatake; K Kangawa
Journal:  Circulation       Date:  2000-08-22       Impact factor: 29.690

Review 5.  Brain natriuretic peptide: diagnostic and therapeutic implications in pulmonary arterial hypertension.

Authors:  C William Hargett; Victor F Tapson
Journal:  Semin Respir Crit Care Med       Date:  2005-08       Impact factor: 3.119

6.  Development of the new lung allocation system in the United States.

Authors:  T M Egan; S Murray; R T Bustami; T H Shearon; K P McCullough; L B Edwards; M A Coke; E R Garrity; S C Sweet; D A Heiney; F L Grover
Journal:  Am J Transplant       Date:  2006       Impact factor: 8.086

7.  Thoracic organ transplantation in the United States, 1995-2004.

Authors:  J B Orens; T H Shearon; R S Freudenberger; R S Freudenburger; J V Conte; S M Bhorade; A Ardehali
Journal:  Am J Transplant       Date:  2006       Impact factor: 8.086

8.  Survival in primary pulmonary hypertension: the impact of epoprostenol therapy.

Authors:  Vallerie V McLaughlin; Alicia Shillington; Stuart Rich
Journal:  Circulation       Date:  2002-09-17       Impact factor: 29.690

9.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

Authors:  Olivier Sitbon; Marc Humbert; Hilario Nunes; Florence Parent; Gilles Garcia; Philippe Hervé; Maurizio Rainisio; Gérald Simonneau
Journal:  J Am Coll Cardiol       Date:  2002-08-21       Impact factor: 24.094

10.  Survival in patients with primary pulmonary hypertension. Results from a national prospective registry.

Authors:  G E D'Alonzo; R J Barst; S M Ayres; E H Bergofsky; B H Brundage; K M Detre; A P Fishman; R M Goldring; B M Groves; J T Kernis
Journal:  Ann Intern Med       Date:  1991-09-01       Impact factor: 25.391

View more
  33 in total

Review 1.  Update on pulmonary hypertension 2009.

Authors:  Mark T Gladwin; Hossein-Ardeschir Ghofrani
Journal:  Am J Respir Crit Care Med       Date:  2010-05-15       Impact factor: 21.405

Review 2.  Selecting lung transplant candidates: where do current guidelines fall short?

Authors:  Jaime L Hook; David J Lederer
Journal:  Expert Rev Respir Med       Date:  2012-02       Impact factor: 3.772

Review 3.  Current clinical management of pulmonary arterial hypertension.

Authors:  Roham T Zamanian; Kristina T Kudelko; Yon K Sung; Vinicio de Jesus Perez; Juliana Liu; Edda Spiekerkoetter
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

4.  The utility of 6-minute walk distance in predicting waitlist mortality for lung transplant candidates.

Authors:  Anthony Castleberry; Michael S Mulvihill; Babatunde A Yerokun; Brian C Gulack; Brian Englum; Laurie Snyder; Mathias Worni; Asishana Osho; Scott Palmer; R Duane Davis; Matthew G Hartwig
Journal:  J Heart Lung Transplant       Date:  2016-12-30       Impact factor: 10.247

5.  Successful lung transplant from donor after cardiac death: a potential solution to shortage of thoracic organs.

Authors:  Stephen H McKellar; Lucian A Durham; John P Scott; Stephen D Cassivi
Journal:  Mayo Clin Proc       Date:  2010-02       Impact factor: 7.616

6.  Lung Transplantation in Cystic Fibrosis: Trends and Controversies.

Authors:  Joshua Blatter; Stuart Sweet
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2015-12-01       Impact factor: 1.349

7.  Characteristics of patients with pulmonary venoocclusive disease awaiting transplantation.

Authors:  Keith M Wille; Nirmal S Sharma; Tejaswini Kulkarni; Matthew R Lammi; Joseph B Barney; S Christopher Bellot; Ryan S Cantor; David C Naftel; Enrique Diaz-Guzman; David C McGiffin
Journal:  Ann Am Thorac Soc       Date:  2014-11

8.  Disparities in lung transplantation before and after introduction of the lung allocation score.

Authors:  Keith M Wille; Kathy F Harrington; Joao A deAndrade; Sonia Vishin; Robert A Oster; Richard A Kaslow
Journal:  J Heart Lung Transplant       Date:  2013-04-09       Impact factor: 10.247

9.  Causes and circumstances of death in pulmonary arterial hypertension.

Authors:  Adriano R Tonelli; Vineesha Arelli; Omar A Minai; Jennie Newman; Nancy Bair; Gustavo A Heresi; Raed A Dweik
Journal:  Am J Respir Crit Care Med       Date:  2013-08-01       Impact factor: 21.405

10.  Use of a low-resistance compliant thoracic artificial lung in the pulmonary artery to pulmonary artery configuration.

Authors:  Christopher N Scipione; Rebecca E Schewe; Kelly L Koch; Andrew W Shaffer; Amit Iyengar; Keith E Cook
Journal:  J Thorac Cardiovasc Surg       Date:  2013-02-10       Impact factor: 5.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.